By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Salix Pharmaceuticals, Ltd. 

1700 Perimeter Park Drive

Morrisville  North Carolina  27560  U.S.A.
Phone: 919-862-1000 Fax: 919-862-1095


SEARCH JOBS


Industry
Pharmaceutical






Company News
Salix Pharmaceuticals, Ltd. (SLXP)’s TARGET 3 Study Examines The Safety And Efficacy Of Repeat Treatment With Rifaximin 550 mg For Irritable Bowel Syndrome With Diarrhea 10/21/2014 11:09:20 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis 10/8/2014 11:09:50 AM
Progenics Pharmaceuticals, Inc. (PGNX) Pockets A $40 Million Milestone Payment From Salix Pharmaceuticals, Ltd. (SLXP) 10/7/2014 6:45:32 AM
Salix Pharmaceuticals, Ltd. (SLXP) To Ring The Nasdaq Stock Market Closing Bell 10/3/2014 10:34:39 AM
Salix Pharmaceuticals, Ltd. (SLXP) Linked With Actavis (ACT) After Calling Off Cosmo Pharmaceuticals S.p.A. Merger Amid Inversion Crackdown 10/3/2014 5:51:58 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain 9/30/2014 11:07:53 AM
Allergan Inc. (AGN) Rejected Actavis (ACT), Continues Courting Salix Pharmaceuticals, Ltd. (SLXP) 9/22/2014 5:47:22 PM
Salix Pharmaceuticals, Ltd. (SLXP) Secures Additional Intellectual Property Relating To Rifaximin 9/18/2014 9:17:33 AM
Salix Pharmaceuticals, Ltd. (SLXP) Faces Shareholder Revolt On Cosmo Pharmaceuticals S.p.A. Deal 9/17/2014 6:33:51 AM
Salix Pharmaceuticals, Ltd. (SLXP) Release: UCERIS® (budesonide) 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA 9/16/2014 8:49:54 AM
12345678910...
//-->